These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 23873099)

  • 1. Twist: a molecular target in cancer therapeutics.
    Khan MA; Chen HC; Zhang D; Fu J
    Tumour Biol; 2013 Oct; 34(5):2497-506. PubMed ID: 23873099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation.
    Lee HJ; Li CF; Ruan D; Powers S; Thompson PA; Frohman MA; Chan CH
    Mol Cell; 2016 Sep; 63(6):1021-33. PubMed ID: 27618486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twist as a new prognostic marker in hematological malignancies.
    Norozi F; Ahmadzadeh A; Shahjahani M; Shahrabi S; Saki N
    Clin Transl Oncol; 2016 Feb; 18(2):113-24. PubMed ID: 26203802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
    Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
    J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
    Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
    Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
    Zhang YQ; Wei XL; Liang YK; Chen WL; Zhang F; Bai JW; Qiu SQ; Du CW; Huang WH; Zhang GJ
    PLoS One; 2015; 10(8):e0135851. PubMed ID: 26295469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin suppresses lung cancer metastasis by inhibition of epithelial-mesenchymal transition through targeting to Twist.
    Chao CC; Chen PC; Chiou PC; Hsu CJ; Liu PI; Yang YC; Reiter RJ; Yang SF; Tang CH
    Clin Sci (Lond); 2019 Mar; 133(5):709-722. PubMed ID: 30808718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers.
    Wallerand H; Robert G; Pasticier G; Ravaud A; Ballanger P; Reiter RE; Ferrière JM
    Urol Oncol; 2010; 28(5):473-9. PubMed ID: 19272800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel.
    Cheng GZ; Chan J; Wang Q; Zhang W; Sun CD; Wang LH
    Cancer Res; 2007 Mar; 67(5):1979-87. PubMed ID: 17332325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1α translational pathway in colorectal cancer cells.
    Chang LH; Chen CH; Huang DY; Pai HC; Pan SL; Teng CM
    J Cell Physiol; 2011 Apr; 226(4):1060-8. PubMed ID: 20857420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1.
    Cao J; Wang X; Dai T; Wu Y; Zhang M; Cao R; Zhang R; Wang G; Jiang R; Zhou BP; Shi J; Kang T
    Theranostics; 2018; 8(10):2739-2751. PubMed ID: 29774072
    [No Abstract]   [Full Text] [Related]  

  • 13. The twist box domain is required for Twist1-induced prostate cancer metastasis.
    Gajula RP; Chettiar ST; Williams RD; Thiyagarajan S; Kato Y; Aziz K; Wang R; Gandhi N; Wild AT; Vesuna F; Ma J; Salih T; Cades J; Fertig E; Biswal S; Burns TF; Chung CH; Rudin CM; Herman JM; Hales RK; Raman V; An SS; Tran PT
    Mol Cancer Res; 2013 Nov; 11(11):1387-400. PubMed ID: 23982216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HGF and TGFβ1 differently influenced Wwox regulatory function on Twist program for mesenchymal-epithelial transition in bone metastatic versus parental breast carcinoma cells.
    Bendinelli P; Maroni P; Matteucci E; Desiderio MA
    Mol Cancer; 2015 Jun; 14():112. PubMed ID: 26041563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice.
    Chen S; Chen JZ; Zhang JQ; Chen HX; Yan ML; Huang L; Tian YF; Chen YL; Wang YD
    Cancer Lett; 2016 Dec; 383(1):73-84. PubMed ID: 27693633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of the transcription factor twist in phenotype alteration through epithelial-mesenchymal transition in lung cancer cells.
    Nakashima H; Hashimoto N; Aoyama D; Kohnoh T; Sakamoto K; Kusunose M; Imaizumi K; Takeyama Y; Sato M; Kawabe T; Hasegawa Y
    Mol Carcinog; 2012 May; 51(5):400-10. PubMed ID: 21594904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.
    Yang L; Hou Y; Yuan J; Tang S; Zhang H; Zhu Q; Du YE; Zhou M; Wen S; Xu L; Tang X; Cui X; Liu M
    Oncotarget; 2015 Sep; 6(28):25755-69. PubMed ID: 26342198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moscatilin inhibits migration and metastasis of human breast cancer MDA-MB-231 cells through inhibition of Akt and Twist signaling pathway.
    Pai HC; Chang LH; Peng CY; Chang YL; Chen CC; Shen CC; Teng CM; Pan SL
    J Mol Med (Berl); 2013 Mar; 91(3):347-56. PubMed ID: 22961111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twist promotes tumor cell growth through YB-1 expression.
    Shiota M; Izumi H; Onitsuka T; Miyamoto N; Kashiwagi E; Kidani A; Yokomizo A; Naito S; Kohno K
    Cancer Res; 2008 Jan; 68(1):98-105. PubMed ID: 18172301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
    Bahar E; Kim JY; Kim HS; Yoon H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.